GlassScriptPhysician profile
Laura Effinger Harris
NPI 1295721348
$2,088.60
in general payments reported to CMS, 2019-2025
27 companies · $374 in 2025
The $374 reported for 2025 was more than what 87% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $189 · 2021: $366 · 2022: $418 · 2023: $275 · 2024: $265 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884 · Long Term Medical Supply Or Device Loan: $28.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.38 |
| Long Term Medical Supply Or Device Loan | $28.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $328.68 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Cranial Technologies, INC | $306.74 | 2020-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $191.80 | 2024-2025 | |
| Pfizer INC. | $190.50 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $128.52 | 2021-2023 | Qelbree |
| Kaleo, INC. | $125.80 | 2019-2023 | Auvi-Q |
| Corium, LLC | $124.22 | 2021-2023 | Azstarys |
| Glaxosmithkline, LLC. | $102.93 | 2019-2025 | Bexsero |
| Abbott Laboratories | $85.99 | 2025 | Cardiomems |
| Sanofi Pasteur INC. | $68.40 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $53.58 | 2019-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $48.02 | 2023-2024 | Flumist Quadrivalent |
| Welch Allyn | $47.52 | 2020 | |
| Seqirus USA INC | $36.11 | 2022-2025 | Flucelvax |
| Shire North American Group INC | $29.66 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $28.51 | 2025 | Hillrom - Spot Vision Screener |
| Boston Scientific Corporation | $24.26 | 2021 | |
| Lnhc, INC | $23.48 | 2025 | Zelsuvmi |
| Takeda Pharmaceuticals U.S.A., INC. | $18.47 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.63 | 2022 | |
| Genentech USA, INC. | $17.29 | 2019 | |
| Adlon Therapeutics L.P. | $15.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.77 | 2019 | |
| Phadia US INC. | $12.87 | 2021 | |
| Neos Therapeutics, LP | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.